Business
Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs
CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics
About this update from Denali Therapeutics Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), where she founded the Rare Diseases Program and predominantly focused on rare diseases drug review. \n\n \n \n \n \n \n \n\n \n\"Anne has been an exceptional force in government organizations, first at the FDA and then at the NIH, to propel rare disease research, translational science, and drug development,\" said Lovisa Afzelius, Ph.D., MBA, Origination Partner at Flagship Pioneering and Founding CEO of Alltrna. \"We are thrilled she has joined our team to lead Alltrna's strategy for regulatory and medical research as we leverage tRNA biology as a platform approach to treat many diseases with a single medicine.\"\n\"I'm so impressed with the vision and motivation of the team at Alltrna to pursue a 'many-diseases-at-a-time' strategy with the focus of making a significant impact on the treatment of rare diseases,\" said Dr. Pariser. \"As a therapeutic mechanism, tRNA has this unique potential to treat thousands of different diseases with a precision medicine approach. Alltrna's deep and systematic exploration of tRNA biology creates a very exciting way to explore the nearly limitless potential of tRNA medicines.\"\nDuring her tenure at ORDR, Dr. Pariser oversaw the Rare Diseases Clinical Research Network (RDCRN), a network of rare diseases research consortia focusing on research programs into more than 200 different rare diseases and other research programs. Additional research programs included the PaVe-GT gene therapy development program, which seeks to treat four ultra-rare diseases using a platform approach, grant programs to speed rare disease diagnoses and many-diseases-at-a-time strategies, and rare...